HongKong:01801

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, July 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-07-26 08:00 6347

Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 7717

Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 7945

Innovent Provides Update on ctDNA in Predicting Response and Resistance by Anti-PD-1 Therapy in Chinese Relapsed/Refractory Classical Hodgkin Lymphoma

SUZHOU, China, June 3, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the results of circulating tumor DNA (ctDNA) for predicting response and resistance ...

2019-06-04 08:00 3836
123